Your browser doesn't support javascript.
loading
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Sehn, Laurie H; Hertzberg, Mark; Opat, Stephen; Herrera, Alex F; Assouline, Sarit; Flowers, Christopher R; Kim, Tae Min; McMillan, Andrew; Ozcan, Muhit; Safar, Violaine; Salles, Gilles; Ku, Grace; Hirata, Jamie; Chang, Yi Meng; Musick, Lisa; Matasar, Matthew J.
Afiliação
  • Sehn LH; BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada.
  • Hertzberg M; Prince of Wales Hospital and University of New South Wales, Sydney, NSW, Australia.
  • Opat S; Clinical Haematology, Monash Health and Monash University, Clayton, VIC, Australia.
  • Herrera AF; City of Hope Medical Centre, Duarte, CA.
  • Assouline S; Jewish General Hospital, Montreal, QC, Canada.
  • Flowers CR; Winship Cancer Institute of Emory University, Atlanta, GA.
  • Kim TM; Seoul National University Hospital, Seoul, South Korea.
  • McMillan A; Center for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Ozcan M; Ankara University, Ankara, Turkey.
  • Safar V; Centre Hospitalier Lyon-Sud, Lyon, France.
  • Salles G; Centre Hospitalier Lyon-Sud, Lyon, France.
  • Ku G; Genentech, Inc., South San Francisco, CA.
  • Hirata J; Genentech, Inc., South San Francisco, CA.
  • Chang YM; F. Hoffmann-La Roche Ltd., Mississauga, ON, Canada; and.
  • Musick L; Genentech, Inc., South San Francisco, CA.
  • Matasar MJ; Memorial Sloan-Kettering Cancer Center, New York, NY.
Blood Adv ; 6(2): 533-543, 2022 01 25.
Article em En | MEDLINE | ID: mdl-34749395

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Imunoconjugados Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Imunoconjugados Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article